{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:06:42Z","timestamp":1792073202608,"version":"4.4.0"},"reference-count":92,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with <jats:italic>BRAF<\/jats:italic> V600E\u2013 or HER2 amplification\u2013positive disease.<\/jats:p>","DOI":"10.6004\/jnccn.2020.0032","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T19:18:01Z","timestamp":1594149481000},"page":"806-815","source":"Crossref","is-referenced-by-count":403,"title":["NCCN Guidelines Insights: Rectal Cancer, Version 6.2020"],"prefix":"10.6004","volume":"18","author":[{"given":"Al B.","family":"Benson","sequence":"first","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[{"name":"2UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Al-Hawary","sequence":"additional","affiliation":[{"name":"3University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa A.","family":"Arain","sequence":"additional","affiliation":[{"name":"2UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"4City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen K.","family":"Ciombor","sequence":"additional","affiliation":[{"name":"5Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Cohen","sequence":"additional","affiliation":[{"name":"6Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry S.","family":"Cooper","sequence":"additional","affiliation":[{"name":"7Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Deming","sequence":"additional","affiliation":[{"name":"8University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[{"name":"9Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Grem","sequence":"additional","affiliation":[{"name":"10Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gunn","sequence":"additional","affiliation":[{"name":"11O\u2019Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffe","sequence":"additional","affiliation":[{"name":"12Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[{"name":"13Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hunt","sequence":"additional","affiliation":[{"name":"14Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Kirilcuk","sequence":"additional","affiliation":[{"name":"15Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Krishnamurthi","sequence":"additional","affiliation":[{"name":"16Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[{"name":"17University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"18Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Miller","sequence":"additional","affiliation":[{"name":"19The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Mulcahy","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Nurkin","sequence":"additional","affiliation":[{"name":"20Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"21The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Parikh","sequence":"additional","affiliation":[{"name":"22Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitendra","family":"Patel","sequence":"additional","affiliation":[{"name":"23UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Pedersen","sequence":"additional","affiliation":[{"name":"14Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[{"name":"24Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schneider","sequence":"additional","affiliation":[{"name":"25Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shibata","sequence":"additional","affiliation":[{"name":"26The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Skibber","sequence":"additional","affiliation":[{"name":"21The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[{"name":"24Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Stoffel","sequence":"additional","affiliation":[{"name":"3University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Stotsky-Himelfarb","sequence":"additional","affiliation":[{"name":"27The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Willett","sequence":"additional","affiliation":[{"name":"28Duke Cancer Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyse","family":"Johnson-Chilla","sequence":"additional","affiliation":[{"name":"29National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Gurski","sequence":"additional","affiliation":[{"name":"29National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref831","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]","volume":"35","author":"Kopetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2005.04.4875","article-title":"Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer","volume":"24","author":"Chau","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"iv154","DOI":"10.1093\/annonc\/mdz183.004","article-title":"BEACON CRC: a randomized, 3-arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E\u2013mutant metastatic colorectal cancer [abstract]","volume":"30","author":"Kopetz","year":"2019","journal-title":"Ann Oncol"},{"key":"ref931","article-title":"package insert Thousand CA","author":"Kanjinti","year":"2019"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"ref281","article-title":"package insert","author":"Vitrakvi","year":"2018","journal-title":"Oncology"},{"key":"ref441","article-title":"package insert Thousand CA","author":"Kanjinti","year":"2019"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/annonc\/mdw215","article-title":"PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer","volume":"27","author":"Sclafani","year":"2016","journal-title":"Ann Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J","article-title":"Patterns of pelvic recurrence following definitive resections of rectal cancer","volume":"53","author":"Pilipshen","year":"1984","journal-title":"Cancer"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref461","article-title":"package insert Station Merck","author":"Ontruzant","year":"2019"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clinimag.2015.10.006","article-title":"Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience","volume":"40","author":"Revelli","year":"2016","journal-title":"Clin Imaging"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref961","article-title":"package insert New York","author":"Trazimera","year":"2019"},{"key":"ref411","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3517","article-title":"HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]","volume":"34","author":"Raghav","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0000000000000149","article-title":"Complete neoadjuvant treatment of rectal cancer: the Brown University Oncology Group CONTRE study","volume":"40","author":"Perez","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/3-540-27449-9_15","article-title":"Operative treatment of locally recurrent rectal cancer","volume":"165","author":"Wiig","year":"2005","journal-title":"Recent Results Cancer Res"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.seminoncol.2007.03.005","article-title":"Surgical management of rectal cancer","volume":"34","author":"Rajput","year":"2007","journal-title":"Semin Oncol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2214\/AJR.11.7602","article-title":"Recognition of the anterior peritoneal reflection at rectal MRI","volume":"200","author":"Gollub","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","article-title":"Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial","volume":"26","author":"Fernandez-Martos","year":"2015","journal-title":"Ann Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/93.8.583","article-title":"Guidelines 2000 for colon and rectal cancer surgery","volume":"93","author":"Nelson","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.seminoncol.2007.03.005","article-title":"Surgical management of rectal cancer","volume":"34","author":"Rajput","year":"2007","journal-title":"Semin Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","article-title":"Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial","volume":"26","author":"Fernandez-Martos","year":"2015","journal-title":"Ann Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J","article-title":"Patterns of pelvic recurrence following definitive resections of rectal cancer","volume":"53","author":"Pilipshen","year":"1984","journal-title":"Cancer"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"ref941","article-title":"package insert GmbH","author":"Ogivri","year":"2019"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/annonc\/mdw215","article-title":"PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer","volume":"27","author":"Sclafani","year":"2016","journal-title":"Ann Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00464-015-4067-3","article-title":"Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference","volume":"29","author":"Morino","year":"2015","journal-title":"Surg Endosc"},{"key":"ref341","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]","volume":"35","author":"Kopetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"513","DOI":"10.6004\/jnccn.2014.0056","article-title":"Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer","volume":"12","author":"Cercek","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10350-004-0930-3","article-title":"Surgical salvage of recurrent rectal cancer after transanal excision","volume":"48","author":"Weiser","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"ref91","first-page":"CD008997","article-title":"Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer","volume":"8","author":"Cirocchi","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"key":"ref761","article-title":"package insert South San CA","author":"Rozlytrek","year":"2019"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/SLA.0000000000003251","article-title":"Definition of the rectum: an international, expert-based Delphi consensus","volume":"270","author":"D\u02bcSouza","year":"2019","journal-title":"Ann Surg"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00464-015-4067-3","article-title":"Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference","volume":"29","author":"Morino","year":"2015","journal-title":"Surg Endosc"},{"key":"ref901","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3517","article-title":"HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]","volume":"34","author":"Raghav","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref581","first-page":"CD008997","article-title":"Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer","volume":"8","author":"Cirocchi","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/SLA.0000000000003251","article-title":"Definition of the rectum: an international, expert-based Delphi consensus","volume":"270","author":"D\u02bcSouza","year":"2019","journal-title":"Ann Surg"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON Colorectal Cancer study","volume":"37","author":"Van Cutsem","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2006.09.7840","article-title":"Organ preservation for rectal cancer","volume":"25","author":"Baxter","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/3-540-27449-9_15","article-title":"Operative treatment of locally recurrent rectal cancer","volume":"165","author":"Wiig","year":"2005","journal-title":"Recent Results Cancer Res"},{"key":"ref951","article-title":"package insert Station Merck","author":"Ontruzant","year":"2019"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1634\/theoncologist.2010-0285","article-title":"Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study","volume":"16","author":"Nogu\u00e9","year":"2011","journal-title":"Oncologist"},{"key":"ref921","article-title":"package insert Pharmaceuticals","author":"Herzuma","year":"2019","journal-title":"USA"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10350-004-0930-3","article-title":"Surgical salvage of recurrent rectal cancer after transanal excision","volume":"48","author":"Weiser","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"ref271","article-title":"package insert South San CA","author":"Rozlytrek","year":"2019"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0000000000000149","article-title":"Complete neoadjuvant treatment of rectal cancer: the Brown University Oncology Group CONTRE study","volume":"40","author":"Perez","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"ref771","article-title":"package insert","author":"Vitrakvi","year":"2018","journal-title":"Oncology"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON Colorectal Cancer study","volume":"37","author":"Van Cutsem","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdr473","article-title":"Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study","volume":"23","author":"Mar\u00e9chal","year":"2012","journal-title":"Ann Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdr473","article-title":"Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study","volume":"23","author":"Mar\u00e9chal","year":"2012","journal-title":"Ann Oncol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2005.04.4875","article-title":"Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer","volume":"24","author":"Chau","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"iv154","DOI":"10.1093\/annonc\/mdz183.004","article-title":"BEACON CRC: a randomized, 3-arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E\u2013mutant metastatic colorectal cancer [abstract]","volume":"30","author":"Kopetz","year":"2019","journal-title":"Ann Oncol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/93.8.583","article-title":"Guidelines 2000 for colon and rectal cancer surgery","volume":"93","author":"Nelson","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2214\/AJR.11.7602","article-title":"Recognition of the anterior peritoneal reflection at rectal MRI","volume":"200","author":"Gollub","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref431","article-title":"package insert Pharmaceuticals","author":"Herzuma","year":"2019","journal-title":"USA"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/COC.0b013e3181fe41ed","article-title":"Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005","volume":"34","author":"Cheng","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1634\/theoncologist.2010-0285","article-title":"Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study","volume":"16","author":"Nogu\u00e9","year":"2011","journal-title":"Oncologist"},{"key":"ref451","article-title":"package insert GmbH","author":"Ogivri","year":"2019"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clinimag.2015.10.006","article-title":"Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience","volume":"40","author":"Revelli","year":"2016","journal-title":"Clin Imaging"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"513","DOI":"10.6004\/jnccn.2014.0056","article-title":"Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer","volume":"12","author":"Cercek","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"ref471","article-title":"package insert New York","author":"Trazimera","year":"2019"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2006.09.7840","article-title":"Organ preservation for rectal cancer","volume":"25","author":"Baxter","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/COC.0b013e3181fe41ed","article-title":"Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005","volume":"34","author":"Cheng","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/7\/article-p806.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/7\/article-p806.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T20:09:55Z","timestamp":1596830995000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/7\/article-p806.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":92,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.0032","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}